Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Interest Expense

Cost of servicing the company's debt during the period.

Benitec Biopharma Inc.NASDAQ: BNTC

Interest Expense · Q3 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q3 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearJun 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 interest expense of $0 is the 8th highest of the 10 companies compared; the peer median is $5.02M.
BNTC Competitors Peer median
Interest Expense for BNTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTCPureTech Health plcFY2025$45.78M +356.1%+126.2%982.5%
AUTLAutolus Therapeutics plcLTM Mar 2026$44.43M +26345.5%+60.4%48.0%
XOMAXOMA Royalty Corp.LTM Mar 2026$12.92M -6.1%—35.7%
GALTGalectin Therapeutics Inc.LTM Mar 2026$7.57M +21.5%+92.2%—
OCGNOcugen, Inc.LTM Mar 2026$5.02M +449.6%—112.5%
SLDBSolid Biosciences Inc.LTM Mar 2026$60K -80.8%——
NGNENeurogene Inc.LTM Mar 2026$3K -72.7%+35.7%—
BNTCBenitec Biopharma Inc.LTM Mar 2026$0 ———
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
QSIQuantum-Si incorporatedLTM Mar 2026$0 ——0.0%
Peer median (excluding BNTC) $5.02M+21.5%+76.3%41.8%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue59K73K75K00
Cost of Revenue123K9K0343K0
Gross Profit(64K)64K75K(343K)(396K)
Gross Margin-108.5%87.7%100.0%——
Research & Development7.02M11.27M12.77M15.61M18.33M
Selling, General & Admin6.51M6.65M6.38M6.99M23.43M
Operating Expenses13.53M17.92M19.16M22.49M41.77M
Depreciation & Amortization424K392K381K343K396K
EBITDA(13.45M)(17.78M)(18.7M)(22.15M)(41.37M)
EBITDA Margin-22800.0%-24361.6%-24933.3%——
Operating Income(13.6M)(17.85M)(19.08M)(22.49M)(41.77M)
Operating Margin-23044.1%-24457.5%-25441.3%——
Interest Income000904K0
Interest Expense6K32K33K00
Other Income / Expenses(286K)(354K)(481K)739K3.85M
Income Before Tax(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Pre-Tax Margin-23528.8%-24942.5%-26082.7%——
Income Tax Expense00000
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Net Margin-23528.8%-24942.5%-26082.7%——
EPS (Basic)(27.27)(19.31)(14.12)(2.68)(1.05)
EPS (Diluted)(27.27)(19.31)(14.12)(2.68)(1.05)
Weighted Avg Shares1.01M1.92M1.39M10.26M36.21M
Weighted Avg Shares (Diluted)1.01M1.92M1.39M10.28M36.21M

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.